Synovial Fibroblast 3.1: Secretion response of seven primary human synovial fibroblast samples from healthy and rheumatoid arthritis donors to a panel of 3 stimuli and 5 small molecule inhibitors (replicate 1 of 2) - Dataset (ID:20234)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
---|---|---|---|---|---|---|---|---|---|---|---|
RA1869 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 1 | MIP-1A | 96.0 | 41 | |
RA1869 | IL-1 alpha | 100 | ng/mL | 1 | MIP-1A | 122.0 | 41 | ||||
N2759 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 1 | MIP-1A | 504.0 | 61 | |
N2759 | IL-1 alpha | 100 | ng/mL | 1 | MIP-1A | 372.0 | 47 | ||||
RA1931 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 1 | MIP-1A | 626.0 | 49 | |
RA1931 | IL-1 alpha | 100 | ng/mL | 1 | MIP-1A | 698.0 | 37 | ||||
N2586 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 1 | MIP-1A | 215.0 | 47 | |
N2586 | IL-1 alpha | 100 | ng/mL | 1 | MIP-1A | 221.0 | 52 | ||||
RA1869 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 1 | MIP-1A | 22.0 | 44 | |
RA1869 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 1 | MIP-1A | 22.0 | 62 | |
N2759 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 1 | MIP-1A | 23.0 | 57 | |
N2759 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 1 | MIP-1A | 20.0 | 45 | |
RA1931 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 1 | MIP-1A | 23.5 | 52 | |
RA1931 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 1 | MIP-1A | 24.0 | 52 | |
N2586 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 1 | MIP-1A | 22.0 | 40 | |
N2586 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 1 | MIP-1A | 23.0 | 50 | |
RA1869 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 1 | MIP-1A | 38.0 | 39 | |
RA1869 | Poly(I:C) | 2 | ug/mL | 1 | MIP-1A | 81.0 | 42 | ||||
N2759 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 1 | MIP-1A | 665.5 | 56 | |
N2759 | Poly(I:C) | 2 | ug/mL | 1 | MIP-1A | 384.0 | 54 | ||||
RA1931 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 1 | MIP-1A | 526.0 | 54 | |
RA1931 | Poly(I:C) | 2 | ug/mL | 1 | MIP-1A | 737.0 | 53 | ||||
N2586 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 1 | MIP-1A | 54.0 | 56 | |
N2586 | Poly(I:C) | 2 | ug/mL | 1 | MIP-1A | 106.0 | 43 | ||||
RA1869 | 5z-7-oxozeaenol | 0.6 | uM | 1 | MIP-1A | 22.0 | 56 |